Pharma, Biotech, VCs Must Unite to Get Drugs to Market
Senior Staff Writer
PHILADELPHIA – With lengthy development cycles and the increasing costs of clinical work, well-established therapeutics sitting on pharmaceutical company shelves may be the lowest hanging fruit.
The question is: Who is going to pay for them? Big pharmas are challenged to bring all of the promising products to market, despite budget constraints; biotechs are challenged to find funding for their own technologies; and venture capital firms are challenged to get returns on investments.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST